Sources close to the Trump administration said they expect vaccine-sceptical rhetoric and policy actions to resume in the coming months, Axios reports

Sources close to the Trump administration said they expect vaccine-sceptical rhetoric and policy actions to resume in the coming months, Axios reports.

Sourced reports of this kind, attribution to unnamed figures close to an administration, sit at the weaker end of the policy-signal spectrum; the historical pattern is that they move sectors only where the named official has confirmed form, and here vaccine-sceptical positioning from this political circle is well established rather than new information. The transmission channel in past episodes has run through the vaccine-exposed pharma names and the broader healthcare complex rather than through macro assets, with the distinction that matters being rhetoric versus concrete policy action: appointments, funding decisions, and regulatory guidance have durable effects on the peer set, while rhetoric alone has tended to fade within sessions. The wide macro tag set on the headline overstates the likely footprint; FX and energy have no direct channel here. What has historically mattered next is confirmation, whether the rhetoric is followed by personnel moves at health agencies or formal policy steps, since that is where precedent shows the repricing becoming persistent rather than transient. As an unsourced-expectation story, the first tell is whether the named actors repeat the signal on the record.